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A B S T R A C T
Introduction: Local failure (LF) following stereotactic radiosurgery (SRS) of brain metastases (BM) may be
treated with a second course of SRS (SRS2), though this procedure may increase the risk of symptomatic
radionecrosis (RN).
Methods: A literature search was conducted according to PRISMA to identify studies reporting LF, overall sur-
vival (OS) and RN rates following SRS2. Meta-analysis was performed to identify predictors of RN.
Results: Analysis included 11 studies (335 patients,389 metastases). Pooled 1-year LF was 24 %(CI95 % 19–30
%): heterogeneity was acceptable (I2= 21.4 %). Median pooled OS was 14 months (Confidence Interval 95 %,
CI95 % 8.8–22.0 months). Cumulative crude RN rate was 13 % (95 %CI 8 %–19 %), with acceptable hetero-
geneity (I2=40.3 %). Subgroup analysis showed higher RN incidence in studies with median patient age ≥59
years (13 % [95 %CI 8 %–19 %] vs 7 %[95 %CI 3 %–12 %], p= 0.004) and lower incidence following prior
Whole Brain Radiotherapy (WBRT, 19 %[95 %CI 13 %–25 %] vs 7%[95 %CI 3 %–13 %], p=0.004).
Conclusions: SRS2 is an effective strategy for in-site recurrence of BM previously treated with SRS.
1. Introduction
Approximately 20 % of cancer patients will develop brain metas-
tases (BM) during the clinical course of their disease, in particular
melanoma, lung and breast cancer (Achrol et al., 2019). Most notably,
this figure is expected to increase due to earlier BM detection and im-
proved efficacy of systemic therapies, allowing for extended extra cra-
nial disease control (Nieder et al., 2011). However, prognosis after
occurrence of BM is still dismal, with an expected 2-years survival rate
of 8.1 % (Achrol et al., 2019).
Following results from recent clinical trials, stereotactic radio-
surgery (SRS) has become a valuable option in patients with limited
intracranial disease burden and a favorable life expectancy, with local
control rates of approximately 70 % at 1 year (Aoyama et al., 2006;
Shaw et al., 2000; Rades et al., 2007) and a relatively benign toxicity
profile in terms of neurocognitive impairment as compared to Whole
Brain RadioTherapy (WBRT) (Chang et al., 2009). This comes at the
price of a non-negligible risk of symptomatic radionecrosis (RN), an
irreversible, radiation-induced, delayed brain injury that manifests in
median 5 months (Stafinski et al., 2006) from treatment and is asso-
ciated to progressive clinical deterioration and variable neurological
impairment depending on the lesion location. This severe adverse
event, occurring in up to 11 % of cases at 24 months (Stafinski et al.,
2006), has been correlated to multiple clinical and treatment-related
features (Blonigen et al., 2010; Flickinger et al., 2000; Sneed et al.,
2015; Stumpf et al., 2019; Kim et al., 2017; Miller et al., 2016). RN
proves also challenging on a diagnostic point of view, since histological
assessment is often difficult to obtain or misleading due to sampling
errors related to possible coexistence of residual cancer cells and ne-
crotic material in the biopsy (Narloch et al., 2017), while no single
morphologic and/or metabolic imaging modality proved to be con-
clusive in differentiating RN from tumor recurrence (Vellayappan et al.,
2018). Focusing on outcome, at present, no firm consensus has been
established on the adequate treatment modality for patients experien-
cing local failure in BMs previously treated with SRS (Rae et al., 2016).
Salvage options include chemotherapy, surgery, WBRT or supportive
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care: however, no clear evidence is available concerning the superiority
of one modality over another, and no consensual recommendations
have been formulated at present on this topic (Ammirati et al., 2010).
Surgical resection may be considered as the preferred salvage modality,
allowing for pathological assessment and providing, both in case of RN
or tumor progression, removal of the causative process and prompt
symptoms relief (Kano et al., 2009; Truong et al., 2006; Telera et al.,
2013; Szeifert et al., 2006; Jagannathan et al., 2010; Vecil et al., 2005);
however, it is unlikely that patients who were not initially eligible for
surgical excision (a procedure that confers the highest local control
rates in association to adjuvant SRS (Mahajan et al., 2017)), may re-
ceive surgery at the time of recurrence. WBRT, in consideration of
neurocognitive impairment and disappointing results in terms of dis-
ease control, is usually deferred until onset of symptoms or proposed in
case of multifocal relapse in patients with an uncontrolled primary
tumor (McTyre et al., 2018). Concerning chemotherapy, significant
heterogeneity exists with regard to tumor- (expected chemo-sensitivity)
and drug-related variables, in particular blood-brain-barrier (BBB) pe-
netration (Venur and Ahluwalia, 2016).
In the last 10 years, an increasing use of stereotactic reirradiation
(SRS2) has been reported in the setting of recurrent brain metastases.
However, this approach has been questioned both in terms of efficacy
and tolerability. In the first instance, it is controversial whether a
second course of radiotherapy might be effective following prior se-
lection of purportedly radio-resistant clones (Kuwahara et al., 2018).
Secondarily, and most notably, SRS2 might be correlated to an in-
acceptable risk of adverse events, resulting in a cumulative 1-year
symptomatic RN incidence of 20 % (Sneed et al., 2015).
We performed a systematic review and meta-analysis of the litera-
ture reporting outcomes and toxicity of patients receiving SRS2 for
locally recurrent BMs following prior SRS.
2. Material and methods
2.1. Selection criteria and search strategy
A systematic review of the published literature was performed ac-
cording to the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) criteria. Due to lack of comparator in this
setting, the PICO model was not applicable. Relevant articles were
identified searching three electronic database (Pubmed, Scopus,
Cochrane Library) by 4 authors (ML, DG, GF, KD) with use of the ap-
propriate MeSH terms for the following search items: "brain", "en-
cephalic", "cerebral" AND "stereotactic", "SRS", "radiosurgery" AND
"reirradiation", "re irradiation", "salvage", "repeated", "repeat" AND
"metastases", "metastatic", "metastasis", "in-field relapse", "in-field pro-
gression", "local relapse", "local failure".
Only fully published, peer-reviewed articles in English assessing the
use of repeated stereotactic irradiation of brain metastases up to 1st
November 2019 were included in our analysis. For the purpose of our
study, case reports or in-silico case studies were not considered; papers
analyzing use of SRS following exclusive WBRT or a second course of
SRS for out-of-field progression were likewise excluded from analysis.
In summary, only selected studies addressing patients who received two
sequential SRS to the same brain metastasis due to intercurrent local
failure were included in the final analysis. Duplicated studies or studies
with insufficiently reported outcomes were removed. To verify the
compliance to the predetermined search criteria, an evaluation was
independently carried out by 2 author’s teams (ML,GF,GS,PB;
KD,DG,ID,SC); in case of inconsistency or disagreement between teams,
a final decision was formulated with a third team (JN, LL, SS). The
search methodology is summarized in Fig. 1.
2.2. Validity assessment
For each individual study, the risk of bias in each study was
evaluated through the ROBINS-I (Sterne et al., 2016) tool to evaluate
the following domains: a) bias due to confounding of effects; b) bias in
selection of participants; c) bias due to classification of interventions; d)
bias due to deviations from intended interventions; e) bias due to
missing data; f) bias in measurement of the outcome; and g) bias in
selection of the reported result.
2.3. Data extraction and statistical analysis
Data extraction from included articles was performed by one author
team (ML,GF,GS,PB) and data accuracy was verified by a second team
(KD,DG,ID,SC). Patients’, disease and treatment-related features as well
as local control rates and incidence of RN were collected and reported
using descriptive statistics.
The study-specific median OS were pooled into a summary value
and corresponding 95 % confidence intervals (CI) by applying the
“weighted median of medians” method (R statistical software, library
metamedian; see McGrath et al. for reference (McGrath et al. (2019))).
When not explicitly reported in the text, median OS was manually ex-
tracted from Kaplan-Meier survival curves (available for all remaining
studies with the exception of one study). The study-specific proportion
of patients experiencing a local failure at 6 and 12 months during
follow-up, or radio necrosis at any time after SRS2, were pooled into
summary proportions and corresponding 95 % CI using random-effects
models implemented in the metaprop command in Stata (StataCorp,
College Station, TX, USA, version 14) (Higgins and Thompson, 2002).
The heterogeneity between studies was quantified using the I2 statistics,
which can be interpreted as the proportion of variability across esti-
mates that is due to actual heterogeneity rather than chance (Guan
et al., 2019). Values of I2 above 50 % are considered as denoting large
heterogeneity: when this occurs, fitting meta-regression and subgroup
analysis models (for continuous and categorical variables, respectively)
is recommended in order to find study characteristics that correlate
with the outcome and can therefore explain part of the heterogeneity.
For the model focusing on the proportion of radionecrosis, some sub-
group analyses where, however, conducted regardless of the value
taken by the I2 statistics using the following variables that were sus-
pected a priori to be possibly associated with the outcome: patient’s age;
biologically equivalent dose (BED) and irradiated volume of SRS2, and
its delay from SRS1; and proportion of patients with prior whole brain
irradiation (WBRT) or receiving SRS2 with a multi-fractionated sche-
dule.
3. Results
Search workflow is outlined in Fig. 1. Thirty-two full-text papers
were initially included out of 1136 potential references after check for
duplicate or pertinence. Among them, 21 were excluded due to lack of
prior SRS to the target metastasis (previous WBRT only, or first ste-
reotactic irradiation of the target lesion after prior SRS to another in-
tracranial site, or mixed interventions) or insufficient data reporting
(Guan et al. (2019); Maranzano et al., 2019; Kim et al., 2018; Koiso
et al., 2016; Huang et al., 2017; Shen et al., 2016; Bates et al., 2016;
Yomo and Hayashi, 2016; Shultz et al., 2015; Monaco et al., 2014;
Kurtz et al., 2014; Kim et al., 2013; Maranzano et al., 2012; Kwon et al.,
2007a; Shuto et al., 2004; Hillard et al., 2003; Wowra et al., 2002;
Bhatnagar et al., 2002; Noël et al., 2001; Davey et al., 1994; Kwon
et al., 2007b). Hence, eleven studies were considered eligible for data
extraction and included in the final meta-analysis (Iorio-Morin et al.,
2019; Dincoglan et al., 2019; Moreau et al., 2018; Balermpas et al.,
2018; Rana et al., 2017; McKay et al., 2017; Minniti et al., 2016; Greto
et al., 2014; Terakedis et al., 2014; Holt et al., 2015; Koffer et al., 2020),
accounting for 335 patients and 389 treated metastases. Median follow-
up was available for 10/11 studies: for the pooled population, median
follow-up was 12 (1–124) months.
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3.1. Validity of included studies
The study design was retrospective in all cases. Risk of bias in in-
dividual studies is reported in Table 1. Risk of confounding bias was
found low or unclear in all studies due to presence of possible un-
controlled confounders such as differences in primary tumor type and
systemic treatments, prior administration of other local treatment, use
of different dose regimens at first and second SRS, variability in age and
performance status. Nevertheless, despite significant heterogeneity in
the study population, risk level was not considered critical with regards
to decision to treatment across the studies due to accurate reporting of
clinical and treatment variables in most included papers.
Due to retrospective nature of all the studies, presence of significant
selection bias cannot be excluded. However, prespecified use of con-
sistent criteria for differential diagnosis between local failure and RN
(both at the time of allocation to treatment and at response evaluation)
within each study should be sufficient to minimize risk of selection bias
in each cohort.
No major classification bias was highlighted due to clear definition
of treatment procedures in all studies. Moreover, due to short duration
of the proposed intervention (1–3 daily fractions), no major deviations
from the planned treatment were reported in any study.
Risk of bias in measurement of the reported results was mostly low
due to consistent use of validated methodology such as increased
Relative Cerebral Blood Volume>2 (rCBV) at perfusion Magnetic
Resonance Imaging (MRI) (Dincoglan et al., 2019; Minniti et al., 2016;
Fig. 1. Summary of the search methodology reported as a flow diagram.
Table 1
Risk of bias summary: review authors’ judgements about each risk of bias item for each included study. Low: (+), moderate: (++), unclear: (?).
Study Confounding Selection Classification Deviation Missing Measurement Reported
Terakedis (?) (+) (+) (+) (+) (+) (++)
Greto (+) (+) (+) (+) (++) (+) (++)
Minniti (+) (+) (+) (+) (+) (+) (++)
McKay (?) (+) (+) (+) (+) (+) (++)
Rana (+) (+) (+) (+) (++) (+) (++)
Balermpas (+) (+) (+) (+) (+) (+) (++)
Moreau (+) (+) (+) (+) (++) (+) (++)
Dincoglan (+) (+) (+) (+) (+) (+) (++)
Holt (+) (?) (+) (+) (+) (++) (++)
Koffer (?) (+) (+) (+) (+) (+) (++)
Iorio-Morin (?) (+) (+) (+) (+) (+) (++)
M. Loi, et al. Critical Reviews in Oncology / Hematology 153 (2020) 103043
3
Koffer et al., 2020) and consensual diagnostic criteria such as RECIST
(Rana et al., 2017; McKay et al., 2017; Greto et al., 2014; Terakedis
et al., 2014; Holt et al., 2015), RANO-BM (Iorio-Morin et al., 2019;
Moreau et al., 2018) and iRANO (Balermpas et al., 2018). However
variability of criteria in use across the different studies is of concern, in
particular with regard to the image modality of choice.
Risk of bias for missing data was found low in the majority of the
examined papers due to enforcement of an adequate follow-up schedule
with regard to the expected time to efficacy and toxicity event, with the
exception of 2 studies due to short or unreported (Rana et al., 2017;
Greto et al., 2014) duration of median follow-up. However, a general
lack of analytic strategies for dealing with loss of information was
found. The risk of selective report was considered moderate for all the
studies due to lack of statistic strategies to account for competing events
(death for extracranial progression), despite the use of a clearly defined
estimate of the outcome and toxicity of the intervention. Overall, no
critical bias risk was found in any study, though inter-study variability,
in particular with regard to different modalities of outcome measure-
ment, is of concern.
3.2. Clinical and treatment-related characteristics
Clinical and treatment related characteristics for all studies are
summarized in Tables 2 and 3, respectively. Median age, reported in all
studies, was 59 years (range 27–88). Karnofsky Performance Status
(KPS) was present in 8/11 studies, showing a KPS > 70 % in 117/214
(55 %) patients. Information concerning primary tumor were found in
all studies, though only 8/11 studies reported this data on a per-patient
basis. Hence, out of 288 assessable patients, lung cancer (101/288, 35
%), melanoma (70/288, 24 %) and breast (62/288, 22 %) cancer were
the most represented histology. Pathological assessment was performed
only in 34 out of 153 metastases from 5/11 studies. In the remaining
cases, diagnosis of recurrence was based on contrast-enhanced (CE)
MRI, perfusion MRI, perfusion MRI plus spectroscopy and perfusion
MRI plus DOTA-PET CT in respectively 6, 2, 2, and 1 studies. Surgical
excision at any time point before SRS2 was acknowledged in 8/11
studies, and was performed in 89/249 (36 %) patients: in all cases,
however, residual disease was present at the time of SRS2. Information
on WBRT was available in all studies: WBRT was delivered at any time
point before SRS2 in approximately one third of cases (102/335, 30 %).
Median dose delivered at the time of first SRS (SRS1) was reported in 8/
11 studies, corresponding to a median prescription dose of 20 (18–24)
Gy in 1 fraction. Time interval between SRS1 and SRS2 was reported in
all the studies, corresponding to a median 13 (6–19) months delay.
Median tumor volume at reirradiation was 12 (1–40) cc. Median
dose delivered at the time of SRS2 was 19 (15.5–26.5) Gy in 1 (1–3)
fraction, translating into an extrapolated median Biological Effective
Dose (BED) of 50.4 Gy assuming an α/β=10. Treatment was delivered
using a single-fraction and a multifractionated regimen in respectively
72 % (280/389) and 28 % (109/389) patients.
3.3. Local control and overall survival
In the pooled population from eleven studies, 6-months and 1-year
local failure estimates were 7 % (CI95 % 4–12 %) and 24 % (CI95 %
19–30 %). Acceptable heterogeneity was found in both cases (I2= 35.3
% and 21.4 %, respectively) (Fig. 2 A). Five studies reported on pre-
dictive factors correlated to increased local failure risk, including pri-
mary tumor type (melanoma versus other histotypes), lack of prior
WBRT, tumor size at SRS2, prescription dose at SRS2, initial best re-
sponse at first SRS, KPS, and controlled extracranial disease (see
Table 4).
Pooled estimate of median survival was obtained from 9 studies,
resulting in a median pooled OS of 14 months (CI95 % 8.8–22.0
months). Among the predictive factors, only lower prescription dose at







































































































































































































































































































































































































































































































































































































































































































































Cumulative RN rate was calculated from eleven studies, resulting in
a crude median value of 13 % (95 %CI 8 %–19 %) in the pooled po-
pulation at the end of the follow-up period, with a moderate, yet ac-
ceptable heterogeneity (I2= 40.3 %) (Fig. 2 B). Since no study reported
neither mean nor total follow-up, pooled estimate of the incidence was
not assessable. Median time from SRS2 to RN was reported in 4 studies,
ranging from 3 to 8 months (median 4 months). Risk factors for RN are
reported in Table 4. A trend for increased risk in case of prior WBRT
was observed in one study, though not reaching statistical significance
(p=0.05). A meta-regression for variables uniformly reported across
the pooled population (see Table 3) was not contributive due to in-
sufficient number of included studies. Therefore, a subgroup analysis
was carried out to compare median values and the correspondent per-
centage of RN: a significantly higher incidence of RN was found in
studies with median age ≥ 59 years (n=6, 13 % [95 %CI 8 %–19 %]
vs 7% [95 %CI 3 %–12 %], p= 0.004) and prior use of WBRT in≤29 %
of the study population (n=6, 19 % [95 %CI 13 %–25 %] vs 7 % [95
%CI 3 %–13 %], p=0.004). No significant differences in terms of RN
among studies was found with regard to median prescribed BED, tumor
volume and use of a multifractionated schedule at SRS2. Median in-
terval from SRS1 to SRS2, albeit yielding a moderate difference be-
tween RN rates for studies reporting a delay superior (n= 4, 18 % [95
%CI 10 %-2 %]) versus equal or inferior to 13 months (n=7, 10 % [95
%CI 5 %–16 %]), did note prove significant at statistical analysis
(p= 0.148, NS).
4. Discussion
Limited data are available concerning the optimal salvage modality
following in-site recurrence of brain metastases after upfront SRS.
Treatment options include surgical excision, chemotherapy or re-
irradiation by WBRT or SRS2. Decision is often based on patient’s age
and functional status, extracranial disease control, intracranial tumor
burden, previous treatment and type of primary cancer (Ammirati et al.,
2010). Whenever feasible, surgical excision is the preferred option,
allowing for discrimination between tumor recurrence and RN and re-
sulting in satisfactory local control rates ranging from 62 %–93 % at
1 year (Kano et al., 2009; Truong et al., 2006; Vecil et al., 2005) and a
median survival of 8.7 months after surgery (Truong et al., 2006).
However, its use is currently restricted to selected cases, accounting for
1–11 % of patients eligible for salvage treatment of recurrent BM (Rae
et al., 2016; Szeifert et al., 2006), in consideration of its invasive
character that may be related to a non-negligible mortality and mor-
bidity risk (Kano et al., 2009). Despite introduction of less invasive
modalities such as laser-interstitial thermal therapy (LITT), a neuro-
surgical approach does not obviate for subsequent use of reirradiation
to confer additional local control benefit in most cases (Hong et al.,
2019).
Table 3





































Terakedis 43 43 17 18 9 18 1 43 0 0 50,4 2,2
Greto 13 13 6 n/a 13 19 1 9 4 36 53,5 40,0
Minniti 43 43 0 n/a 17 21 3 0 43 100 35,7 12,0
McKay 46 46 8 20 19 20 1 46 0 0 60 1,0
Rana 32 32 8 24 10 26.5 3 19 13 40 65,1 1,35
Balermpas 32 32 4 18 12 19 1 24 8 25 50,4 2,5
Moreau 36 36 24 n/a 15 18 1 36 0 0 50,4 4,8
Dincoglan 30 30 0 18 14 21 3 0 30 100 35,7 14,0
Holt 15 15 1 21 6,4 21 3 6 9 60 35,7 9,8
Koffer 24 24 8 18 13 15,5 1 24 0 0 33 3,3
Iorio-Morin 75 75 26 20 13 18 1 75 0 0 50,4 1,19
Summary 335 389 102 20* 13 19 1 282 107 28 50,4 3,30
Fig. 2. (A) Forest plot of studies evaluating SRS2: effect on 1-year Local Control (LC). WBRT: Whole Brain Radiotherapy. SRS: Stereotactic Radiosurgery (B) Forest
plot of studies evaluating SRS2: effect on Radionecrosis (RN) crude incidence. ES: Effect Size.
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In our meta-analysis, we addressed the use of a second course of SRS
to recurrent BM. Eleven retrospective studies were included, accounting
for 335 patients and 389 treated metastases. Validity assessment using
the ROBINS-I tool was carried out, showing no critical bias risk in each
domain for all the included articles. The most prominent finding in our
study is the pooled 24 % 1-year local failure rate, suggesting that local
control rates following SRS2 do not dramatically differ from those re-
ported by prospective trials of upfront SRS (Aoyama et al., 2006; Shaw
et al., 2000; Stafinski et al., 2006). Most interestingly, median survival
in the pooled population was 14 months from the date of SRS2. This is
similar to median survival following a first course of SRS in selected
subsets, that is approximately 11 months in patients with high score at
GPA prognostic index (Sperduto et al., 2012).
These figures are comparable with outcomes from surgical series
(LC rate of 62 %–93 % at 1 year (Kano et al., 2009; Truong et al., 2006;
Vecil et al., 2005) and median survival of 8.7 months after surgery
(Truong et al., 2006)). However, direct comparison between SRS2 and
resection is hindered by frequent combined reporting of surgical exci-
sion both as salvage therapy for in-field progression of BM and as a
palliation for symptomatic RN to decrease neurologic impairment and
steroid dependency (Jagannathan et al., 2010). Interestingly, local
failure and median survival in the pooled population showed low inter-
studies heterogeneity, with I2< 50 % for both endpoints.
Another major finding in our work is the pooled rate of RN, esti-
mated at 13 % at a median follow up of 12 months. Our finding is in
line with previous reports, that highlighted an increased risk of RN
following SRS2 of brain metastases (Sneed et al., 2015; Minniti et al.,
2016). However, it should be pointed out that incidence of RN is
variable among different salvage modalities for recurrent BM following
SRS. Rae et al. (Rae et al., 2016) reported the risk of RN using different
salvage strategies in patients with recurrent BM after SRS, excluding
SRS2: despite no significant increase in incidence of RN in patients
receiving salvage therapy, a baseline risk of RN was found in 4.5 % of
salvaged patients (all intervention confounded), that rose to 21 % in
patients receiving concurrent SRS to a distant site and WBRT.
Three studies (see Table 4) reported predictive factors correlated to
increased risk of RN, consisting of tumor volume at SRS2, higher pre-
scribed dose at SRS2 and larger overlap area between first SRS and
SRS2 volumes in 2, 2 and 1 studies, respectively. In the subset analysis
carried out on the pooled population, only younger age and prior use of
WBRT were associated to lower RN incidence.
While older age is not a contraindication to SRS, as demonstrated by
previous experiences (Minniti et al., 2013), the correlation between age
and radiation-related brain damage has long been known: the severity
of white-matter alterations have been found to increase with advancing
age, as a possible consequence of age-related underlying vascular and
neurological injury though important inter-individual variability is also
observed (Tsuruda et al., 1987). Comprehensive geriatric assessment,
including evaluation of functional status and comorbidities is strongly
recommended (Frasca et al., 2018).
Focusing on WBRT, a possible protective role may seem counter-
intuitive, but RN is a complex phenomenon in which inflammatory
cells, perivascular lymphocytes, GFAP-positive astrocytes and cytokine
secretion play a key role in chronic inflammatory response (Yoshii,
2008). It could be hypothesized that previous WBRT may contribute to
decreased activity of all elements cooperating in late tissue response to
radiotherapy, delivering lower dose to the whole brain parenchyma and
providing an unfavorable microenvironment to inflammation: thus,
SRS2 may act on a “cold” brain parenchyma, unable to arrange a re-
sponse to radiation damage. More probably, it could be a confirmation
that previous WBRT had inconclusive association with risk of RN, as
shown in several series regarding SRS1 that reported conflicting results
(Sneed et al., 2015; Schüttrumpf et al., 2014; Kohutek et al., 2015;
Donovan et al., 2019), in particular with regard to variable timing of
the procedure and its place in the treatment sequence.
Interestingly, in our analysis, use of fractionated schedules was not
found protective with regard to occurrence of RN, as this strategy is
frequently used to mitigate toxicity in presence of large tumors that
have an intrinsically higher risk of RN (Donovan et al., 2019): for this
reason, no definitive conclusion can be drawn about threshold volume
and optimal radiation schedule in patients who are candidate to SRS2.
It is also noteworthy that interval between the SRS courses did not
significantly influence the onset of RN.
The main limitations of our work refer mainly to the retrospective
nature and the small number of eligible studies identified according to
our search criteria. Moreover, despite use of validated parameters for
the differential diagnosis between progression versus RN and definition
of response following SRS2, a lack of standardized definition for these
events across different series represents a potential source of bias and
should be addressed by consensual use of objective criteria such as the
RANO-BM (Lin et al., 2015). Due to heterogeneity and inconsistent
reporting of primary tumor type and concurrent medications, a possible
impact of tumor histology and systemic therapy (with particular focus
to molecular-targeted agents) could not be ruled out in our analysis. For
these reason, no clear indications can be drawn on patient selection, in
particular with regard to the risk of developing RN after SRS2.
5. Conclusion
In patients experiencing in-site recurrence of BM following upfront
SRS, a second course of SRS (SRS2) is an effective strategy. According to
our meta-analysis SRS results in median overall survival superior to 12
months, while local control rates compares favorably with results from
surgical series. However, SRS2 is associated, in 13 % of pooled patients,
to development of symptomatic RN, a severe adverse event causing
significant psychophysical impairment. Unfortunately, available data
did not allow a robust meta-analysis of predictive factors. Although
younger age and previous use of WBRT were found protective with
regard to RN occurrence at subset analysis, no impact was demon-
strated for tumor volume, use of multifractionated schedules, higher
biological effective dose and longer time interval from first SRS.
Consensual assessment of response using consensual criteria should be
of primary concern in future studies.
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